Conmed (CNMD) Cash from Operations Growth (3y) (2013 - 2026)
Conmed (CNMD) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.44 Bn | 175.14 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 128.91 Bn | 126.03 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 108.67 Bn | 99.45 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 68.45 Bn | 67.00 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 47.59 Bn | 43.92 Bn | 1.29 Bn | -48.14% |
| 6 | Dexcom | 28.59 Bn | 27.48 Bn | 750.30 Mn | 50.11% |
| 7 | GE HealthCare Technologies | 28.53 Bn | 26.24 Bn | 1.98 Bn | -14.75% |
| 8 | Smith & Nephew | 26.95 Bn | 26.37 Bn | - | - |
| 9 | Koninklijke Philips | 25.42 Bn | 22.30 Bn | 2.07 Bn | 0.50% |
| 10 | Conmed | 1.33 Bn | 1.29 Bn | 183.45 Mn | 76.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 76.54% |
| Dec 31, 2025 | 81.66% |
| Sep 30, 2025 | 27.51% |
| Jun 30, 2025 | 15.84% |
| Mar 31, 2025 | 402.16% |
| Dec 31, 2024 | 8.65% |
| Sep 30, 2024 | 33.83% |
| Jun 30, 2024 | 8.10% |
| Mar 31, 2024 | 9.23% |
| Dec 31, 2023 | 40.94% |
| Sep 30, 2023 | 9.51% |
| Jun 30, 2023 | 68.87% |
| Mar 31, 2023 | -44.77% |
| Dec 31, 2022 | -31.69% |
| Sep 30, 2022 | -10.90% |
| Jun 30, 2022 | -4.59% |
| Mar 31, 2022 | 27.73% |
| Dec 31, 2021 | 11.00% |
| Sep 30, 2021 | 69.96% |
| Jun 30, 2021 | 18.45% |